Scarica l'app Stockscreener
4.66
1.53%
0.07
Dopo l'orario di chiusura:
4.59
-0.07
-1.50%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PRTA Giù?
Forum
Previsione
Prothena Corporation Plc Borsa (PRTA) Ultime notizie
ProShare Advisors LLC Buys 3,312 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Chardan Capital Decreases Earnings Estimates for Prothena - Defense World
Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails - MSN
H.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PT - Insider Monkey
FY2027 EPS Estimates for Prothena Decreased by HC Wainwright - Defense World
Prothena (NASDAQ:PRTA) Given “Underperform” Rating at Bank of America - Defense World
Bank of America Reiterates “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World
Prothena’s (PRTA) “Underperform” Rating Reaffirmed at Bank of America - Defense World
The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts - simplywall.st
BofA cuts Prothena stock rating, slashes target to $4 By Investing.com - Investing.com Nigeria
Prothena Corp (PRTA) Sees Downgrade and Price Target Cut by B of A Securities | PRTA Stock News - GuruFocus
Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform - Insider Monkey
BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target - marketscreener.com
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | P - GuruFocus
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | PRTA Stock News - GuruFocus
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down - MSN
Prothena (PRTA) Downgraded by BofA Analyst with Lower Price Targ - GuruFocus
Prothena (NASDAQ:PRTA) Price Target Lowered to $81.00 at Piper Sandler - Defense World
Prothena (NASDAQ:PRTA) Price Target Cut to $29.00 by Analysts at JMP Securities - Defense World
Prothena (NASDAQ:PRTA) Lowered to Hold Rating by Jefferies Financial Group - Defense World
Prothena (NASDAQ:PRTA) Given New $14.00 Price Target at HC Wainwright - Defense World
Traders Purchase High Volume of Put Options on Prothena (NASDAQ:PRTA) - Defense World
Prothena (PRTA) Shares Plunge After Key Trial Setback - GuruFocus
Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place (PRTA) - Seeking Alpha
Peninsula biotech Prothena falters — again — and layoffs are on the waySan Francisco Business Times - The Business Journals
Prothena Shares Fall, Stock Downgraded by Multiple Research Firms After Birtamimab Development Discontinued - marketscreener.com
Prothena Corp (PRTA) Downgraded by Oppenheimer | PRTA Stock News - GuruFocus
Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results - Insider Monkey
Prothena stock hits 52-week low amid downgrades (PRTA:NASDAQ) - Seeking Alpha
Prothena Corp (PRTA) Sees Target Price Reduction by Piper Sandle - GuruFocus
Piper Sandler cuts Prothena stock target to $81 from $110 By Investing.com - Investing.com UK
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Cantor Fitzgerald cuts Prothena stock rating to Neutral By Investing.com - Investing.com UK
Prothena Corp (PRTA) Target Price Slashed by JMP Securities | PRTA Stock News - GuruFocus
Prothena (PRTA) Downgraded Following Unsuccessful Phase 3 Trial - GuruFocus
Expert Outlook: Prothena Corp Through The Eyes Of 5 Analysts - Benzinga
Prothena Corp (PRTA) Analyst Update: Price Target Significantly Lowered | PRTA Stock News - GuruFocus
Why Is Prothena Stock Trading Lower On Tuesday? - Benzinga
Jefferies Downgrades Prothena to Hold From Buy, Adjusts Price Target to $6 From $32 - marketscreener.com
Prothena Corp (PRTA) Price Target Lowered by HC Wainwright & Co. | PRTA Stock News - GuruFocus
Prothena stock price target cut to $14 at H.C. Wainwright By Investing.com - Investing.com UK
Chardan Adjusts PT on Prothena to $18 From $40 After Drug Removal From Model, Keeps Buy Rating - marketscreener.com
Prothena (PRTA) Price Target Slashed Following Clinical Trial Ou - GuruFocus
Prothena (PRTA) Faces Price Target Cut Following Trial Results | PRTA Stock News - GuruFocus
Prothena (PRTA) Target Price Slashed Following Study Setback | P - GuruFocus
Prothena (PRTA) Target Price Slashed Following Study Setback | PRTA Stock News - GuruFocus
Prothena (PRTA) Faces Setback with AFFIRM-AL Trial Results | PRTA Stock News - GuruFocus
Jefferies Downgrades Prothena (PRTA) Following Study Setback | P - GuruFocus
Prothena (PRTA) Downgraded by Oppenheimer After Trial Results | - GuruFocus
Oppenheimer cuts Prothena stock rating after trial setback By Investing.com - Investing.com South Africa
Jefferies cuts Prothena stock rating to hold, slashes target to $6 By Investing.com - Investing.com UK
Prothena’s Phase III trial for AL amyloidosis treatment misses endpoint - Yahoo Finance
Prothena’s SWOT analysis: biotech stock’s high-risk, high-reward pipeline By Investing.com - Investing.com Nigeria
Prothena’s SWOT analysis: biotech stock’s high-risk, high-reward pipeline - Investing.com
6.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):